This is a guest post from Erik Davis of Skeptic North.
**********
Bankers, Buyouts & Billionaires: Why Big Herba’s Research Deficit Isn’t About The Money
It’s a scene from the blogosphere that’s become all too familiar. A skeptic challenges a natural health product for the lack of an evidentiary base. A proponent of that product responds that the skeptic has made a logical error — an absence of evidence is not evidence of absence, and in such a scenario it’s not unreasonable to rely on patient reporting and traditional uses as a guide. The skeptic chimes back with a dissertation on the limits of anecdotal evidence and arguments from antiquity — especially when the corresponding pharma products have a data trail supporting their safety and efficacy. The proponent responds that it’s unfair to hold natural health products to the same evidentiary standard, because only pharma has the money to fund proper research, and they only do so for products they can patent. You can’t patent nature, so no research into natural health products gets done.
Okay, so maybe this isn’t a scene from an actual blog. The participants are way too civil, the arguments too coherent, and no one has been compared to Hitler. But it’s not a straw man either (look here, here, and here for recent examples), merely a distillation of an argument I’ve seen made repeatedly — that the deck has been stacked by Big Pharma, which has set a research bar that the much poorer natural health industry can’t possibly meet given the costs and lack of financial upside.
In my observation, skeptics don’t often have a good response to this argument beyond their basic scientific disposition toward only making assertions based on positive evidence. Typically, that’s not a disposition shared by the proponent, and thus they simply agree to disagree (read: trade barbs until the thread peters out from fatigue). Yet this need not be a purely philosophical debate. After all, there’s a testable premise embedded in this disagreement — that the natural health industry isn’t rich enough to sustain proper research. Is that true? Read more »
Many of my regular readers may know that biomedical research in the United States is largely funded by the National Institutes of Health (NIH). Please see this message from Dr. William Talman, president of the Federation of American Societies for Experimental Biology (FASEB), about proposed spending cuts to the NIH budget. Grant funding from the NIH is already hard to come by, and the proposed budget cuts will make it even harder.
Whether you are a scientist, a student, or a member of the public interested in the future of science and medicine, I join with Dr. Talman in asking you to call your congressional representatives and ask them to oppose HR1. Also, if you have a blog I’d ask you to repost Dr. Talman’s call to action so that your readers can join in.
Dear Colleague,
For months the new House leadership has been promising to cut billions in federal funding in fiscal year (FY) 2011. Later this week the House will try to make the rhetoric a reality by voting on HR 1, a “continuing resolution” (CR) that would cut NIH funding by $1.6 billion (5.2%) BELOW the current level – reducing the budget for medical research to $29.4 billion!
We must rally everyone – researchers, trainees, lab personnel – in the scientific community to protest these draconian cuts. Please go to this FASEB link for instructions on how to call your Representative’s Washington, DC office today! Urge him/her to oppose the cuts to NIH and vote against HR 1. Once you’ve made the call, let us know how it went by sending a short email to the address provided in the call instructions and forward the alert link to your colleagues. We must explain to our Representatives how cuts to NIH will have a devastating impact on their constituents!
Cancer is the world’s costliest disease, sapping the equivalent of 1.5 percent of the global gross domestic product through disability and loss of life, according to the American Cancer Society (ACS). Cancer cost $895 billion in 2008, and that’s before factoring in the cost of treating cancer.
Cancer and other chronic diseases cost more than infectious diseases and even AIDS, according to a report the ACS [presented last] week. While chronic diseases are 60 percent of all deaths globally, they receive only 3 percent of private and public research funding. The organization is calling for a new look at priorities by the United Nations and the World Health Organization. (Associated Press)
*This blog post was originally published at ACP Internist*
The National Institutes of Health (NIH) is the world’s biggest sponsor of research in the life sciences. Today’s biologists, clinical researchers, and many others rely on the NIH for their funding.
To help people better understand how the peer review process happens within the NIH, the agency’s Center for Scientific Review created the following video that includes samples of research being openly discussed by a number of scientists:
Click here to view another video of tips for NIH grant applicants.
*This blog post was originally published at Medgadget*
It’s no secret that doctors are disappointed with the way that the U.S. healthcare system is evolving. Most feel helpless about improving their work conditions or solving technical problems in patient care. Fortunately one young medical student was undeterred by the mountain of disappointment carried by his senior clinician mentors…
I am proud to be a part of the American Resident Project an initiative that promotes the writing of medical students residents and new physicians as they explore ideas for transforming American health care delivery. I recently had the opportunity to interview three of the writing fellows about how to…
I m often asked to do book reviews on my blog and I rarely agree to them. This is because it takes me a long time to read a book and then if I don t enjoy it I figure the author would rather me remain silent than publish my…
When I was in medical school I read Samuel Shem s House Of God as a right of passage. At the time I found it to be a cynical yet eerily accurate portrayal of the underbelly of academic medicine. I gained comfort from its gallows humor and it made me…
I am hesitant to review diet books because they are so often a tangled mess of fact and fiction. Teasing out their truth from falsehood is about as exhausting as delousing a long-haired elementary school student. However after being approached by the authors’ PR agency with the promise of a…
